Transplantation Proceedings
Volume 36, Issue 2 , Pages 364-366 , March 2004

The colon displays an absorptive capacity of tacrolimus

  • K Nishi

      Affiliations

    • Department of Pediatric Surgery, Tohoku University School of Medicine, Sendai, Japan
    • Corresponding Author InformationAddress reprint requests to Kotaro Nishi, Department of Pediatric Surgery, Tohoku University School of Medicine, 1-1 Seiryomachi, Aobaku, Sendai, 980-8574 Japan.
    • ,
  • T Ishii

      Affiliations

    • Department of Pediatric Surgery, Tohoku University School of Medicine, Sendai, Japan
    • ,
  • M Wada

      Affiliations

    • Department of Pediatric Surgery, Tohoku University School of Medicine, Sendai, Japan
    • ,
  • S Amae

      Affiliations

    • Department of Pediatric Surgery, Tohoku University School of Medicine, Sendai, Japan
    • ,
  • N Sano

      Affiliations

    • Department of Pediatric Surgery, Tohoku University School of Medicine, Sendai, Japan
    • ,
  • M Nio

      Affiliations

    • Department of Pediatric Surgery, Tohoku University School of Medicine, Sendai, Japan
    • ,
  • Y Hayashi

      Affiliations

    • Department of Pediatric Surgery, Tohoku University School of Medicine, Sendai, Japan

References 

  1. Venkataramanan R, Swaminathan A, Prasad T, et al.  Clinical pharmacokinetics of Tacrolimus. Clin Pharmacokinet. 1995;29:404
  2. Lampen A, Christians U, Guengerich FP, et al.  Metabolism of the immunosuppressant Tacrolimus in the small intestine (cytochrome P450, drug interactions, and interindividual variability). Drug Metab Dispos. 1995;23:1315
  3. Sano N, Nio M, Shimaoka S, et al.  High trough levels of oral FK506 induced by loss of small intestine. Pediatr Transplant. 2001;5:434
  4. Watanabe Y, Sato M, Abe Y, et al.  Enteric absorption of FK506: estimation by a block liver perfusion technique in rats. Transplant Proc. 1998;30:3777
  5. Paine MF, Khalighi M, Fisher JM, et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1997;283:1552
  6. Lampen A, Christians U, Gonschior AK, et al.  Metabolism of the macrolide immunosuppressant, Tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J Pharmacol. 1996;117:1730
  7. Yasuhara M, Hashida T, Toraguchi M, et al.  Pharmacokinetics and pharmacodynamics of FK506 in pediatric patients receiving living related donor liver transplantations. Transplant Proc. 1995;27:1108
  8. Sattler M, Guengerich FP, Yun C, et al.  Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753
  9. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Delivery Rev. 1997;27:161
  10. Hashimoto Y, Sasa H, Shimomura M, et al.  Effects of intestinal and hepatic metabolism on the bioavailability of Tacrolimus in rats. Pharm Res. 1998;15:1609
  11. Masuda S, Uemoto S, Hashida T, et al.  Effect of intestinal P-glycoprotein on daily Tacrolimus trough level in a living donor small bowel recipient. Clin Pharmacol Ther. 2000;68:98

PII: S0041-1345(03)01324-1

doi: 10.1016/j.transproceed.2003.12.013

Transplantation Proceedings
Volume 36, Issue 2 , Pages 364-366 , March 2004

Article Tools

* Image Usage & Resolution